Treatment of acute myeloid leukemia cell lines with a novel aCDase inhibitor, SACLAC, effectively blocked aCDase activity and induced a decrease in S1P and an increase in total ceramide levels [123]. Here, ASAH1 is linked to acute myeloid leukemia.